Women's health diagnostics startup Nanopath reports $29.9 million in equity and debt sales
A Form D filed November 13 lists $29,891,706 sold to 21 investors from a $36.8 million offering. The company says its test platform is not yet FDA-cleared.
By Funding Desk ·
The short version
- Nanopath's Form D, filed November 13, 2026, lists $29,891,706 of equity and debt sold to 21 accredited investors, out of a $36,760,740 offering.
- The notice does not split the sum between equity and debt, and names no round, price or investor.
- Its earlier notices reported $10.0 million of equity in 2022 and $5.34 million of debt in 2025; with the new one, $45.2 million by our addition.
- The Cambridge company is building rapid point-of-care tests, starting with women's health; it says its platform has not yet been evaluated or cleared by the FDA.
Nanopath Inc, a Cambridge, Massachusetts, company building rapid diagnostic tests for use at the point of care, beginning with women's health, has told the Securities and Exchange Commission that it sold $29,891,706 of equity and debt. Its Form D notice, filed on November 13, 2026, sizes the offering at $36,760,740, which leaves $6,869,034 unsold. The 21 buyers are all accredited investors, and the first sale is dated October 22, 2026. The company claims the Rule 506(b) exemption, paid no sales commissions or finders' fees, and declined to state a revenue range. Co-chief executive Amogha Tadimety signed the notice on November 10.
The filing does not say how much of the money came as equity and how much as debt. Nor does it name a funding round, a share price or any investor. It lists four people: Tadimety and Alison Burklund as executive officers and directors, and Jeff Crowe and Aaron Sandoski as directors.
Three notices since 2022
Nanopath's EDGAR filing list holds three Form D notices. In 2022 it reported $10.0 million of equity sold to 10 investors; its own news page lists an August 2022 announcement of a $10 million Series A. In February 2025 it reported $5,341,000 of debt sold to five investors, out of $6.0 million offered. The new notice is roughly three times the size of the 2022 sale, and the three notices together report $45.2 million. Those comparisons are our arithmetic. The 2022 notice named Burklund, Tadimety and Jeffrey Crowe; Sandoski first appears in the 2025 filing.
| Filed | First sale | Securities | Offering | Sold | Investors |
|---|---|---|---|---|---|
| August 9, 2022 | June 14, 2022 | Equity | $10,000,000 | $10,000,000 | 10 |
| February 6, 2025 | January 24, 2025 | Debt | $6,000,000 | $5,341,000 | 5 |
| November 13, 2026 | October 22, 2026 | Equity and debt | $36,760,740 | $29,891,706 | 21 |
What it is building
According to its technology page, Nanopath uses optical biosensors based on surface plasmon resonance to detect from ten to hundreds of biomarkers at once. It says the method does away with nucleic acid amplification, which it credits with cutting the time to a result. The company describes a cartridge-and-reader system that it says returns results in 10 to 15 minutes during a patient's visit. The same page states that the platform "has not yet been evaluated or cleared by the FDA."
Its vision page says it is starting with women's health, arguing that most point-of-care tests for women, particularly for pelvic and gynecologic infections, have not improved in more than 50 years, and lists urinary tract infections, human papillomavirus, vaginitis and sexually transmitted infections in its pipeline. The company's news page lists a November 2025 announcement that the FDA granted Breakthrough Device designation to its platform for urinary tract infections, and 2026 papers on a test for bacterial vaginosis, one of them comparing it with an FDA-cleared molecular assay. We have not reviewed those papers.
Federal research money
The company has also drawn federal research grants. The federal award database SBIR.gov credits it with three Small Business Innovation Research awards totaling $3,215,324: a 2022 Phase I award from the National Science Foundation for $255,874, a Phase II award from the NSF in 2023 for $997,781, and a 2024 Phase II award from the National Institutes of Health for $1,961,669.
The NIH project aims at a urinary tract infection test that would identify the bacteria and key antibiotic-resistance genes directly from a urine sample in 15 minutes. Its abstract says culture-based testing, today's standard, takes several days on average, leaving patients waiting for targeted antibiotics, and calls empiric treatment of these infections one of the largest contributors to antibiotic resistance. The plan it describes ends with a pilot clinical study, sized at more than 200 in the abstract, run with Brigham and Women's Hospital.
What the exemption allowed
Rule 506(b), the exemption Nanopath claims, is not limited to accredited investors. The SEC's guide to the rule says a company may also sell to as many as 35 investors who are not accredited in any 90-day period, provided each meets, alone or with a representative, a standard of financial knowledge and experience, and receives disclosure documents. Nanopath left unticked the box for sales, made or possible, to such investors. Asked on the form whether the offering is meant to run beyond a year, it answered no. For the debt part of the sale, the filing gives no interest rate, maturity or conversion terms.
Sources
- Nanopath Inc, Form D, accession no. 0001940981-26-000003 (filing data) U.S. Securities and Exchange Commission (EDGAR), November 13, 2026
- Nanopath Inc, Form D, accession no. 0002054472-25-000002 (filing data) U.S. Securities and Exchange Commission (EDGAR), February 6, 2025
- Nanopath Inc, Form D, accession no. 0001940981-22-000001 (filing data) U.S. Securities and Exchange Commission (EDGAR), August 9, 2022
- Nanopath Inc, EDGAR filing list U.S. Securities and Exchange Commission (EDGAR), November 14, 2026
- Nanopath Inc. (company award portfolio) U.S. Small Business Administration (SBIR.gov), November 14, 2026
- Technology Nanopath, November 14, 2026
- Vision Nanopath, November 14, 2026
- News and resources Nanopath, November 14, 2026
- Filing a Form D notice U.S. Securities and Exchange Commission, June 13, 2024
- Private placements - Rule 506(b) U.S. Securities and Exchange Commission, November 14, 2026
Researched and drafted with AI assistance, then checked against the 10 sources above in a separate fact-check on November 14, 2026. Spotted an error? Tell us.